Skip to content

Intravesical injection of botulinum toxin A in patients with refractory interstitial cystitis/ painful bladder syndrome

Intravesical injection of botulinum toxin A in patients with refractory interstitial cystitis/ painful bladder syndrome - Intravesical injection of botulinum toxin A in patients with refractory interstitial cystitis/ painful bladder syndrome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004554
Enrollment
50
Registered
2010-11-15
Start date
2010-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial cystitis/ Painful bladder syndrome (IC/ PBS)

Interventions

Subjects will be treated soon after the randomization, then will have monthly follow up for 12months. Subjects will be observed for a month with present therapy, then have BTX treatment. After the the

Sponsors

Department of Urology, Unversity of Tokyo hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. IC/ PBS patients whose age is between 20 and 80 years. 2. Those who can have informed consent. 3. Those whose VAS score is more than 4 points and both OSSI/ OSPI scores are more than 6 points despite of hydrodistension, oral administration and intravesical therapy at present institution.

Exclusion criteria

Exclusion criteria: 12

Design outcomes

Primary

MeasureTime frame
Subjects are randomized into 2 groups;one is group who will be treated soon after the enrollment, the other will be observed with present therapy for a month, then treated. The primary end point of this study will be the Global response assessment score in these two groups.

Secondary

MeasureTime frame
1.Duration of symptom relief 2.Changes during 12 months after the therapy 1)flow volume chart 2)O'Leary and Sants' symptom index and problem index 3)Visual analogue scale for pain 4)over active bladder symptom score 5)International prostate symptom score 6)Core lower urinary tract symptom score 7)QOL score 8)Global response assessment score

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026